Images List Premium Download Classic

Enzyme Inhibitor

Enzyme Inhibitor-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
Academia Sinica
October 05, 2017 - N°20170283878

The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v ...
Herbicide-tolerant plants
Basf Agrochemical Products, B.v.
September 28, 2017 - N°20170275645

The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant. Plants of the invention may express an acetyl-coenzyme a carboxylase enzyme that is tolerant to the action of acetyl-coenzyme a carboxylase enzyme inhibitors.
Hgh determination for use to guide prevention of a major adverse cardiac event or a ...
Sphingotec Gmbh
August 17, 2017 - N°20170234889

A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e. G. Angiotensin converting enzyme inhibitor (ace inhibitor), angiotensin receptor blocker (arb), beta-adrenoreceptor blocker (beta-blocker) and/or statins) by determining the level of hgh, and/or its isoforms in a blood sample of said subject and comparing ...
Enzyme Inhibitor Patent Pack
Download + patent application PDFs
Enzyme Inhibitor Patent Applications
Download + Enzyme Inhibitor-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Enzyme Inhibitor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Detoxifying and recycling of washing solution used in pretreatment of lignocellulose-containing materials
Cofco Ltd
August 10, 2017 - N°20170226694

The invention relates to a process of detoxifying pretreated lignocellulose-containing material comprising washing the pretreated lignocellulose-containing material in a washing solution and treating the used washing solution to remove an enzyme inhibitor and/or an inhibitor of a fermenting organism before recycling the used washing solution.
Ligand-directed covalent modification of protein
Celgene Car Llc
August 03, 2017 - N°20170218353

The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
Metalloenzyme inhibitor compounds
Celgene Car Llc
May 25, 2017 - N°20170143694

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Enzyme Inhibitor Patent Pack
Download + patent application PDFs
Enzyme Inhibitor Patent Applications
Download + Enzyme Inhibitor-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Enzyme Inhibitor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
Signature Therapeutics, Inc.
May 04, 2017 - N°20170119754

A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the ...
Methods and compositions for regulating conversion of a prodrug to an active pharmaceutical ingredient
Acura Pharmaceuticals, Inc.
April 27, 2017 - N°20170112825

An abuse deterrent pharmaceutical composition including an abuse deterrent pharmaceutical composition including a prodrug of a pharmaceutically active ingredient and an enzyme inhibitor, wherein the enzyme inhibitor retards conversion of the prodrug to the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
Pharmaceutical combination for the treatment of cancer
Piramal Enterprises Limited
April 27, 2017 - N°20170112809

The present invention relates to a pharmaceutical combination comprising a cdk inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a cdk inhibitor and a therapeutically effective amount ...
Urea compounds and their use as enzyme inhibitors
Piramal Enterprises Limited
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Pde9 inhibitors with imidazo triazinone backbone
H. Lundbeck A/s
March 23, 2017 - N°20170081333

This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (i). The present invention further provides a method of treating a subject suffering ...
Hematopoitetic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of ...
The Medical College Of Wisconsin, Inc.
March 23, 2017 - N°20170080055

Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.
Selective chemotherapy treatments and diagnostic methods related thereto
Emory University
February 23, 2017 - N°20170049815

This disclosure relates to methods of identifying subjects that have an increased likelihood of responding to a combination of a poly (adp) ribose polymerase enzyme inhibitor and a platinum based reagent and optionally other anticancer agents in the course of chemotherapy. In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount of a poly (...
Enzyme Inhibitor Patent Pack
Download + patent application PDFs
Enzyme Inhibitor Patent Applications
Download + Enzyme Inhibitor-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Enzyme Inhibitor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
December 22, 2016 - N°20160367591

A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, ...
Method and composition for preventing and treating viral infections
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
December 22, 2016 - N°20160367517

A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase atpase inhibitor, a sialidase enzyme inhibitor, and icam-1 inhibitor which each also down regulate the immune response. The ...
Treatment of viral infections by modulation of host cell metabolic pathways
The Trustees Of Princeton University
December 01, 2016 - N°20160346309

Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i. E., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) ...
Aminoester derivatives
Chiesi Farmaceutici S.p.a.
December 01, 2016 - N°20160346268

Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratrory tract.
Aminoester derivatives
Chiesi Farmaceutici S.p.a.
December 01, 2016 - N°20160346260

Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratory tract.
Bicyclic heterocyclyl derivates as irak4 inhibitors
Aurigene Discovery Technologies Limited
November 24, 2016 - N°20160340366

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (i), which are therapeutically useful as kinase inhibitors, particularly irak4 inhibitors, wherein a, y, z, x1, x2, r1, r3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the ...
Aminoester derivatives
Chiesi Farmaceutici S.p.a.
November 10, 2016 - N°20160326147

Compounds of formula (i) are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
Quinoline derivatives as pde10a enzyme inhibitors
H. Lundbeck A/s
October 20, 2016 - N°20160303120

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10a over other pde subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using ...
Loading